Media centre
Press releases
18/12/2003
Antisoma PLC shareholder approval for completion of placing and open offer
Antisoma plc ("Antisoma"; or the "Company") announces that at an Extraordinary General Meeting held earlier today the Resolutions proposed and required to implement a Placing and Open Offer to raise £15.2 million were duly passed.
On 25 November 2003, the Company announced a Placing and Open Offer of 38,010,941 New Shares at 40 pence per share to raise approximately £15.2 million (approximately £14.0 million net of expenses). 8,171,103 New Shares were placed firm with institutional investors and 29,839,838 New Shares were placed with institutional investors subject to clawback to satisfy valid applications by Qualifying Shareholders of the Company under the Open Offer.
The Open Offer to Qualifying Shareholders closed at 3.00 pm on 17 December 2003. Applications were received in respect of 3,676,779 New Shares, including the 159,790 New Shares the Directors of Antisoma agreed to take up under the Open Offer. These shares, amounting in total to 12.3% of those available under the Open Offer, were therefore clawed back from the allocations of institutional investors. The remaining 26,163,059 New Shares and the 8,171,103 New Shares that were placed firm (constituting a total of 34,334,162 New Shares), will be taken up by new and existing institutional investors pursuant to the Placing by Nomura International plc.
Application has been made to the UK Listing Authority for the New Shares to be admitted to the Official List and to the London Stock Exchange for admission to trading. It is expected that dealings in the New Shares will commence at 8.00 am on 19 December 2003, following their admission to the Official List of the UK Listing Authority and to trading on the market for listed securities of the London Stock Exchange. CREST stock accounts are expected to be credited on 19 December 2003 and definitive share certificates in respect of New Shares are expected to be posted, where applicable, by 29 December 2003.
Commenting, Glyn Edwards, CEO of Antisoma, said, "We're delighted to have successfully completed a £15.2 million fundraising, enabling us to make additional investment in the further development of our cancer drug pipeline."
Enquiries:
| Antisoma plc | +44 (0)20 8799 8200 | |
| Glyn Edwards, Chief Executive Officer | ||
| Raymond Spencer, Chief Financial Officer | ||
| Nomura International plc | +44 (0)20 7521 2000 | |
| Dave Rasouly | ||
| John Milad | ||
| Financial Dynamics: | +44 (0)20 7831 3113 | |
| Ben Atwell | ||
| Sarah MacLeod |
|
This page includes links to documents in Portable Document File (PDF) format. To read PDF documents you may need to download the free Adobe Acrobat Reader. For PDF accessibility help, visit Access Adobe. These links will open in a new browser window. |
Back to top